ARCHIVES
Original Article
Sustainable Innovation in Traditional Snack Packaging: An AI-Enabled Approach to Extend Shelf-Life of Haldiram's Perishable Products
Saurabh Karoo1
Siddharth Gajbhiye2
Yamini B Laxane3
12 Students, Department of Master of Computer Applications, Smt Radhikatai Pandav College of Engineering, Nagpur, Maharashtra, India. 3Professor, Department of Master of Computer Applications, smt Radhikatai Pandav College of Engineering Nagpur, Maharashtra, India.
Published Online: May-August 2025
Pages: 233-238
Cite this article
↗ https://www.doi.org/10.59256/indjcst.20250402032
References
1. American Diabetes Association. Standards of Medical Care in Diabetes—2023. Diabetes Care. 2023;46(Suppl 1):S1-S120. doi:10.2337/dc23-
S001
(For diagnostic/LDL targets in diabetes)
2. Mach F, et al. 2019 ESC/EAS Guidelines for dyslipidaemias. Eur Heart J. 2020;41(1):111-188. doi:10.1093/eurheartj/ehz455
(Key guideline for statin intensity recommendations)
3. Baigent C, et al. Efficacy and safety of statin therapy in CKD: SHARP trial. Lancet. 2011;377(9784):2181-92. doi:10.1016/S0140-
6736(11)60739-3
(Supports CKD subgroup findings)
4. Ramachandran A, et al. Lipid-lowering therapy patterns in India: ICMR-INDIAB study. JAPI. 2021;69:34-39. PMID: 34227781
(Local context for statin use)
5. RMLH Therapeutics Committee. Hospital Formulary 2023-24. New Delhi: RMLH Press; 2023.
(For institutional dosing protocols)
6. Ganga R, et al. Statin myopathy in South Asians: Gene-dose interaction. Indian Heart J. 2022;74(3):211-215. doi:10.1016/j.ihj.2022.04.003
(Safety data specific to Indian population)
7. CTTC Collaborators. LDL effects across statin types: Meta-analysis. JAMA. 2022;327(8):748-759. doi:10.1001/jama.2022.0708
(Context for between-statin differences)
S001
(For diagnostic/LDL targets in diabetes)
2. Mach F, et al. 2019 ESC/EAS Guidelines for dyslipidaemias. Eur Heart J. 2020;41(1):111-188. doi:10.1093/eurheartj/ehz455
(Key guideline for statin intensity recommendations)
3. Baigent C, et al. Efficacy and safety of statin therapy in CKD: SHARP trial. Lancet. 2011;377(9784):2181-92. doi:10.1016/S0140-
6736(11)60739-3
(Supports CKD subgroup findings)
4. Ramachandran A, et al. Lipid-lowering therapy patterns in India: ICMR-INDIAB study. JAPI. 2021;69:34-39. PMID: 34227781
(Local context for statin use)
5. RMLH Therapeutics Committee. Hospital Formulary 2023-24. New Delhi: RMLH Press; 2023.
(For institutional dosing protocols)
6. Ganga R, et al. Statin myopathy in South Asians: Gene-dose interaction. Indian Heart J. 2022;74(3):211-215. doi:10.1016/j.ihj.2022.04.003
(Safety data specific to Indian population)
7. CTTC Collaborators. LDL effects across statin types: Meta-analysis. JAMA. 2022;327(8):748-759. doi:10.1001/jama.2022.0708
(Context for between-statin differences)
Related Articles
2025
Transforming Cyber-Physical Systems: Machine Learning for Secure and Efficient Solutions
2025
Exploring AI Techniques for Quantum Threat Detection and Prevention
2025
Maturity Models for Business Intelligence: An Overview
2025
INSPIRO: An AI Driven Institution Auditor
2025
Adaptive AI Framework for Anomaly Detection and DDoS Mitigation in Distributed Systems
2025
